Citations

Clear

3314 citation(s) found for "Do, Alexander".

The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
Tur, Carmen , Otero‐Romero, Susana , Amato, Maria Pia , Derfuss, Tobias , Pauli, Franziska Di , Abboud, Hesham , Achiron, Anat , Casanova, Jean‐Laurent , Clifford, David B. , Fonderico, Mattia , Gouider, Riadh , Hacohen, Yael , Kappos, Ludwig , Ladeira, Filipa , Louapre, Céline , Magyari, Melinda , Papeix, Caroline , Piehl, Fredrik , Ruíz-Camps, Isabel , Selmaj, Krzysztof , Simpson, Steve , Sıva, Aksel , Vaknin‐Dembinsky, Adi , Weinshenker, Brian G. , Winkelmann, Alexander, Rodas, María Isabel Zuluaga , Tintoré, Mar , Amato, Maria Pia , Derfuss, Tobias , Abboud, Hesham , Achiron, Anat , Dobson, Ruth , Filippi, Massimo , Fitzgerald, Kathryn C , Fonderico, Mattia , Hellwig, Kerstin , Hemmer, Bernhard , Ladeira, Filipa , Lebrun‐Frénay, Christine , Magyari, Melinda , Oreja-Guevara, Celia , Pandit, Lekha , Papeix, Caroline , Portaccio, Emilio , Simpson-Yap, Steve , Siva, Aksel , Sormani, Maria P , Vukusic, Sandra , Wiendl, Heinz , Tintoré, Mar , Weinshenker, Brian G , Casanova, Jean Laurent , Hacohen, Yael , Dubessy, Anne‐Laure , Iacobaeus, Ellen , Mycko, Marcin P. , Bellinvia, Angelo , Boyко, Alexey , Farez, Mauricio , Filippi, Massimo , Mehling, Matthias , Oreja‐Guevara, Celia , Pandit, Lekha , Sørensen, Per Soelberg , Sormani, Maria Pia , Trojano, María , Wiendl, Heinz , Stankoff, Bruno

Mayo Clinic

Multiple Sclerosis Journal | February 24, 2022 | Volume: 28 | Issue: 9 | Pages: 1424-1456

10.1177/13524585211069068 | PMID 35196927 Get It

Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all DMT-associated risks facilitates development of risk mitigation strategies. An international focused workshop with expert-led discussions was sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and was held in April 2021 to review our current knowledge about the risk of infections associated with the use of DMTs for people with MS and NMOSD and corresponding risk mitigation strategies. The workshop addressed DMT-associated infections in specific populations, such as children and pregnant women with MS, or people with MS who have other comorbidities or live in regions with an exceptionally high infection burden. Finally, we reviewed the topic of DMT-associated infectious risks in the context of the current SARS-CoV-2 pandemic. Herein, we summarize available evidence and identify gaps in knowledge which justify further research.
Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
Matteson, Eric L. , Distler, Jörg H. W. , Seibold, James R. , Mittoo, Shikha, Dellaripa, Paul F. , Aringer, Martin , Pope, Janet , Distler, Oliver , James, Alexandra, Schlenker‐Herceg, Rozsa, Stowasser, Susanne , Quaresma, Manuel , Flaherty, Kevin R. , Investigators, the INBUILD Trial, Distler, Jörg H W , Aringer, Martin , Pope, Janet , Distler, Oliver , Kelly, Clive Anthony , Hoffmann‐Vold, Anna‐Maria , James, Alexandra, Investigators, the INBUILD Trial

Mayo Clinic

Arthritis & Rheumatology | February 24, 2022 | Volume: 74 | Issue: 6 | Pages: 1039-1047

10.1002/art.42075 | PMID 35199968 Get It

ObjectiveTo analyze the efficacy and safety of nintedanib in patients with fibrosing autoimmune disease–related interstitial lung diseases (ILDs) with a progressive phenotype.MethodsThe INBUILD trial enrolled patients with a fibrosing ILD other than idiopathic pulmonary fibrosis, with diffuse fibrosing lung disease of >10% extent on high‐resolution computed tomography, forced vital capacity percent predicted (FVC%) ≥45%, and diffusing capacity of the lungs for carbon monoxide percent predicted ≥30% to <80%. Patients fulfilled protocol‐defined criteria for progression of ILD within the 24 months before screening, despite management deemed appropriate in clinical practice. Subjects were randomized to receive nintedanib or placebo. We assessed the rate of decline in FVC (ml/year) and adverse events (AEs) over 52 weeks in the subgroup with autoimmune disease–related ILDs.ResultsAmong 170 patients with autoimmune disease–related ILDs, the rate of decline in FVC over 52 weeks was −75.9 ml/year with nintedanib versus −178.6 ml/year with placebo (difference 102.7 ml/year [95% confidence interval 23.2, 182.2]; nominal P = 0.012). No heterogeneity was detected in the effect of nintedanib versus placebo across subgroups based on ILD diagnosis (P = 0.91). The most frequent AE was diarrhea, reported in 63.4% and 27.3% of subjects in the nintedanib and placebo groups, respectively. AEs led to permanent discontinuation of trial drug in 17.1% and 10.2% of subjects in the nintedanib and placebo groups, respectively.ConclusionIn the INBUILD trial, nintedanib slowed the rate of decline in FVC in patients with progressive fibrosing autoimmune disease–related ILDs, with AEs that were manageable for most patients.
EPPOCRATIS: Expedited Preoperative Point-of-Care Reduction of Fractures to Normalized Anatomy and Three-Dimensional Printing to Improve Surgical Outcomes
Sharaf, Basel, Kuruoglu, Doga, Cantwell, Sean R., Alexander, Amy E., Dickens, Hunter J., Morris, Jonathan M., Sharaf, Basel , Sharaf, Basel A , Kuruoglu, Doga, Cantwell, Sean R., Alexander, Amy E., Dickens, Hunter J., Morris, Jonathan M.

Mayo Clinic

Plastic & Reconstructive Surgery | February 23, 2022 | Volume: 149 | Issue: 3 | Pages: 695-699

10.1097/prs.0000000000008871 | PMID 35196689 Get It

Summary: Virtual surgical planning and three-dimensional printing have been invaluable tools in craniomaxillofacial surgery. From planning head and neck reconstruction to orthognathic surgery and secondary reconstruction of maxillofacial trauma, virtual surgical planning and three-dimensional printing allow the surgeon to rehearse the surgical plan and use patient-specific surgical guides for carrying out the plan accurately. However, the process of virtual surgical planning and three-dimensional printing requires time and coordination between the surgeon on one hand and the biomedical engineers and designers on the other hand. Outsourcing to third-party companies contributes to inefficiencies in this process. Advances in surgical planning software and three-dimensional printing technology have enabled the integration of virtual surgical planning and three-dimensional printing at the treating hospital, the point of care. This allows for expedited use of this process in semiurgent surgical cases and acute facial trauma cases by bringing the surgeon, radiologist, biomedical engineers, and designers to the point of care. In this article, the authors present the utility of EPPOCRATIS, expedited preoperative point of care reduction of fractures to normalized anatomy and three-dimensional printing to improve surgical outcomes, in the management of acute facial trauma.
Response by Egbe to Letter Regarding Article, “Right Heart Dysfunction in Adults With Coarctation of Aorta: Prevalence and Prognostic Implications”
Egbe, Alexander C. , Egbe, Alexander C

Mayo Clinic

Circulation: Cardiovascular Imaging | February 23, 2022 | Volume: 15 | Issue: 3 | Pages: No page available

10.1161/circimaging.122.014007 | PMID 35193362 Get It

Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer
Blarigan, Erin L. Van , Bainter, Tiffany M., Fuchs, Charles S. , Niedzwiecki, Donna , Hantel, Alexander, Benson, Al B. , Atienza, Daniel, Messino, Michael J., Kindler, Hedy L. , Sanoff, Hanna K. , Giovannucci, Edward L. , Ng, Kimmie , Meyerhardt, Jeffrey A. , Meyerhardt, Jeffrey A , Niedzwiecki, Donna , Sanoff, Hanna , Ou, Fang‐Shu , Zhang, Sui , Saltz, Leonard B. , Mayer, Robert J. , Venook, Alan P. , Ogino, Shuji

Mayo Clinic

JAMA Network Open | February 22, 2022 | Volume: 5 | Issue: 2 | Pages: e220145

10.1001/jamanetworkopen.2022.0145 | PMID 35191970 Get It

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia
Kimura, Shunsuke , Montefiori, Lindsey E. , Zhao, Yaqi , Gao, Qingsong , Paietta, Elisabeth , Mead, Paul E., Gu, Zhaohui , Litzow, Mark R. , Rowe, Jacob M. , Luger, Selina M. , Schmidt, Breon , Ekert, Paul G. , Oshlack, Alicia , Grimmond, Sean M. , Rehn, Jacqueline , Breen, James , Meggendorfer, Manja , Walter, Wencke , Kern, Wolfgang , Haferlach, Torsten , Brady, Samuel W. , Zhang, Jinghui , Blombery, Piers , Montefiori, Lindsey , Zhao, Yaqi , Gao, Qingsong , Gu, Zhaohui , Litzow, Mark R. , Hunger, Stephen P , Ryland, Georgina L , Oshlack, Alicia , Grimmond, Sean M , Rehn, Jacqueline , Yeung, David , White, Deborah L , Pui, Ching-Hon , Walter, Wencke , Roberts, Kathryn G , Mullighan, Charles G , Kimura, Shunsuke , Kern, Wolfgang , Iacobucci, Ilaria , Haferlach, Claudia , Laird, Alexander , Stock, Wendy , Hunger, Stephen P. , Aldoss, Ibrahim , Jabbour, Elias , Roberts, Kathryn G. , Mullighan, Charles G.

Mayo Clinic

Blood | February 22, 2022 | Volume: 139 | Issue: 24 | Pages: 3519-3531

10.1182/blood.2022015444 | PMID 35192684 Get It

Abstract Transcriptome sequencing has identified multiple subtypes of B-progenitor acute lymphoblastic leukemia (B-ALL) of prognostic significance, but a minority of cases lack a known genetic driver. Here, we used integrated whole-genome (WGS) and -transcriptome sequencing (RNA-seq), enhancer mapping, and chromatin topology analysis to identify previously unrecognized genomic drivers in B-ALL. Newly diagnosed (n = 3221) and relapsed (n = 177) B-ALL cases with tumor RNA-seq were studied. WGS was performed to detect mutations, structural variants, and copy number alterations. Integrated analysis of histone 3 lysine 27 acetylation and chromatin looping was performed using HiChIP. We identified a subset of 17 newly diagnosed and 5 relapsed B-ALL cases with a distinct gene expression profile and 2 universal and unique genomic alterations resulting from aberrant recombination-activating gene activation: a focal deletion downstream of PAN3 at 13q12.2 resulting in CDX2 deregulation by the PAN3 enhancer and a focal deletion of exons 18-21 of UBTF at 17q21.31 resulting in a chimeric fusion, UBTF::ATXN7L3. A subset of cases also had rearrangement and increased expression of the PAX5 gene, which is otherwise uncommon in B-ALL. Patients were more commonly female and young adult with median age 35 (range,12-70 years). The immunophenotype was characterized by CD10 negativity and immunoglobulin M positivity. Among 16 patients with known clinical response, 9 (56.3%) had high-risk features including relapse (n = 4) or minimal residual disease &gt;1% at the end of remission induction (n = 5). CDX2-deregulated, UBTF::ATXN7L3 rearranged (CDX2/UBTF) B-ALL is a high-risk subtype of leukemia in young adults for which novel therapeutic approaches are required.
Predictors of Recurrence After Sub-total or Near-total Resection of Vestibular Schwannoma: Importance of Tumor Volume and Ventral Extension
Manzoor, Nauman F., Nassiri, Ashley M., Sherry, Alexander D., Dang, Sabina, Yancey, Kristen L., Monsour, Meredith, Perkins, Elizabeth L., Khattab, Mohamed H., Thompson, Reid C., O’Malley, Matthew R., Bennett, Marc L., Rivas, Alejandro C., Haynes, David S., Sherry, Alexander D. , Yancey, Kristen L. , Sherry, Alexander D , Manzoor, Nauman F., Nassiri, Ashley M., Dang, Sabina, Monsour, Meredith A. , Perkins, Elizabeth L., Khattab, Mohamed H., Thompson, Reid C., O’Malley, Matthew R., Bennett, Marc L., Rivas, Alejandro C., Haynes, David S.

Mayo Clinic

Otology & Neurotology | February 21, 2022 | Volume: 43 | Issue: 5 | Pages: 594-602

10.1097/mao.0000000000003477 | PMID 35184072 Get It

Objective: To evaluate the predictors of remnant tumor regrowth and need for salvage therapy after less than gross total resection (GTR) of vestibular schwannoma (VS). Study Design: Retrospective chart review. Setting: Tertiary neurotologic referral center. Patients: Patients who underwent VS resection between 2008 and 2019 either with GTR, near total resection (NTR), and subtotal resection (STR). Interventions: Microsurgical resection, salvage radiosurgery. Main Outcome Measures: Regrowth free interval, salvage free interval, tumor doubling rate. Results: Three hundred eighty five cases (GTR = 236, NTR = 77, and STR = 71) from 2008 to 2019 were included. STR cohort had much larger and complex tumors with significant differences in tumor volume, ventral extension and brainstem compression (p < 0.001). On single predictor analysis, tumor volume, ventral extension, brainstem compression as well as STR strategy was associated with significant increased risk of regrowth and need for salvage therapy. Multivariate analysis revealed STR strategy as significant predictor of regrowth (hazard ratio 3.79, p < 0.0005). Absolute remnant volume and extent of resection (EOR) did not predict regrowth. A small proportion of cases (NTR = 4%, STR = 15%) eventually needed salvage radiosurgery with excellent ultimate local tumor control with no known recurrence to date. Conclusions: Conservative surgical strategy employing NTR or STR can be employed safely in large and complex VS. While there is increased risk of regrowth in the STR cohort, excellent local control can be achieved with appropriate use of salvage radiosurgery. No disceret radiologic or operative predictors of regrowth were identified.
Impact of lymph node yield at prostatectomy on outcomes in NRG/RTOG 9601.
Chan, Emily , Pugh, Stephanie L. , Simko, Jeff, Feng, Felix Y. , Shipley, William U. , Lukka, Himanshu, Bahary, Jean-Paul , Pisansky, Thomas M. , Zeitzer, Kenneth L. , Lawton, C.A., Balogh, Alexander G., Lovett, R.D., Wong, Anthony , Dess, Robert T. , McGinnis, Scott, Kuettel, Michael, DeMora, Lyudmila, Dess, Robert T , Efstathiou, Jason A. , Rosenthal, Seth A. , McGinnis, Scott, Sandler, Howard M.

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: 265-265

10.1200/jco.2022.40.6_suppl.265 Get It

265 Background: A recent study ( Fossati et al, 2018) found that higher lymph node count at radical prostatectomy was associated with improved outcomes in patients treated with salvage radiation for elevated prostate-specific antigen (PSA) after surgery. We sought to validate these results in NRG/RTOG 9601, a randomized controlled trial of men with pT2/T3 disease who underwent either radiation (RT) alone or RT+antiandrogen (bicalutamide) therapy for PSA elevation following radical prostatectomy from 1998-2003. Methods: We reviewed available pathology reports for all patients in NRG/RTOG 9601 to determine the nodal count at radical prostatectomy. Clinical data was as of 11/5/2015, same as the primary endpoint for the trial. Cox proportional hazards models were used to assess the effect of number of positive lymph nodes, treatment arm (RT alone or RT+bicalutamide), Gleason score, positive margins, and seminal vesicle invasion on the following endpoints: times to local and distant failure and overall and disease specific survival. Results: Out of the 760 patients originally eligible in the trial, 552 (73%, 276 in each arm) had complete data available. Median node count in the entire cohort was 6 (range 0-33, Q1-Q3 3-9). There were no significant differences between treatment arms in terms of patient demographic or clinical characteristics, including total lymph nodes removed in either arm (RT alone vs RT+bicalutamide median 5 vs 6, p = 0.11). There was no significant association between total lymph nodes and overall survival with both arms combined (HR = 1.00, 95% CI:0.97-1.03, p = 0.87) or in the individual arms alone (RT+Casodex: HR = 1.01, 95% CI:0.97-1.05, p = 0.65; RT+Placebo: HR = 0.98, 95% CI: 0.94-1.03, p = 0.45). There was also no significant association between total lymph nodes and disease-specific survival with both arms combined (HR = 1.00, 95% CI:0.95-1.04, p = 0.84) and in the arms alone (RT+Casodex: HR = 1.00, 95% CI:0.95-1.05, p = 0.92; RT+Placebo: HR = 0.99, 95% CI: 0.92-1.07, p = 0.86). In multivariable analysis performed on the two arms, Gleason score was the only feature associated with worse overall and disease-specific survival, seen only in the RT alone arm. Similar findings were seen when evaluating times to local and distant failure. Conclusions: Lymph node yield in NRG/RTOG 9601 did not show any association with adverse outcomes in the entire cohort, or in either treatment arm alone. The therapeutic benefit of an extensive lymph node dissection in this population remains uncertain. Clinical trial information: NCT00002874.
Orbital and Periorbital Dysmorphology in Untreated Pfeiffer Syndrome
Lu, Xiaona, Forte, Antonio Jorge, Allam, Omar, Park, Kitae Eric, Wilson, Alexander, Alperovich, Michael, Steinbacher, Derek M., Tonello, Cristiano, Alonso, Nivaldo, Persing, John A., Forte, Antonio J. , Lu, Xiaona , Alonso, Nivaldo , Forte, Antonio Jorge , Lu, Xiaona, Allam, Omar, Park, Kitae Eric, Wilson, Alexander, Alperovich, Michael, Steinbacher, Derek M., Tonello, Cristiano, Persing, John A.

Mayo Clinic

Plastic & Reconstructive Surgery | February 16, 2022 | Volume: 149 | Issue: 4 | Pages: 731e-742e

10.1097/prs.0000000000008928 | PMID 35171849 Get It

Background: Visual impairment secondary to orbital and periorbital dysmorphology is frequent in Pfeiffer syndrome patients. The etiopathogenesis of this aberrancy, however, remains unclear. Methods: Untreated Pfeiffer syndrome patients (n = 31) and normal control subjects (n = 43) were compared. Craniometric and volumetric analyses related to the orbital and periorbital anatomy were performed using Materialise (Leuven, Belgium) software. Results: Overall, orbital cavity volume of Pfeiffer patients is reduced by 28 percent (p < 0.001), compared to normal, starting before 3 months of age (p = 0.004). Globe volume was diminished by 10 percent (p = 0.041) before 3 months of age, yet tended to catch up thereafter. However, the retrobulbar soft-tissue volume remained smaller beyond 1 year of age (17 percent, p = 0.003). Globe volume projection beyond the bony orbit increased in all observed ages (82 percent, p < 0.001). The volumes of sphenoid bone, maxilla, and mandible proportionately were restricted by 24 to 25 percent (p = 0.003 to 0.035) before 3 months of age. The volume of maxilla and mandible gradually approximate normal; however, the sphenoid bone volume in Pfeiffer patients remains less than normal (p = 0.002) into childhood. The anteroposterior length of both the zygoma and the maxilla was reduced by 14 percent (p < 0.001). Anterior positioning of the zygoma is less by 23 percent (p < 0.001) in Pfeiffer patients overall, with anterior positioning of maxilla reduced similarly by 23 percent (p < 0.001). Conclusions: Pfeiffer syndrome patients develop decreased retrobulbar soft-tissue and globe volume, along with a restricted orbital cavity volume in infancy. Significant hypoplasia of the sphenoid bone is associated with more severe central facial (maxilla) retrusion, compared to lateral facial structures (zygoma). CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, II.
The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease
Liang, Minrui , Matteson, Eric L. , Abril, Andy , Distler, Jörg H. W.

Mayo Clinic

Therapeutic Advances in Musculoskeletal Disease | February 15, 2022 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/1759720x221074457 | PMID 35186127 Get It

The major pulmonary complication of rheumatoid arthritis (RA) is interstitial lung disease (ILD), which causes significant morbidity and mortality and influences the natural course of disease. Recent advances in the management of arthritis have improved patient outcomes. However, exceptionally high medical needs still remain for effective therapies for the patients with ILD in RA. Better understanding of the shared and distinct pathophysiology of fibrotic diseases led to the development of novel antifibrotic agents such as nintedanib and pirfenidone. The further stratification analysis of the phase III INBUILD trial demonstrated beneficial effects of nintedanib in RA-ILD with a progressive phenotype by reducing the rate of decline in forced vital capacity (FVC) over 52 weeks by 60%. Pirfenidone is another antifibrotic agent currently under phase II clinical study (TRAIL1) aiming to evaluate its effects for RA-ILD. This review provides an overview of state-of-the-art pathogenesis and the current therapeutic options for RA-ILD, with a focus on antifibrotic strategies.